Should I buy or sell CASI Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CASI shares. View CASI analyst ratings or view top-rated stocks .

What is CASI Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued 12-month price targets for CASI Pharmaceuticals' shares. Their CASI share price targets range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 114.7% from the stock's current price. View analysts price targets for CASI or view top-rated stocks among Wall Street analysts .

How have CASI shares performed in 2023?

CASI Pharmaceuticals' stock was trading at $1.79 at the start of the year. Since then, CASI stock has increased by 212.3% and is now trading at $5.59. View the best growth stocks for 2023 here .

Are investors shorting CASI Pharmaceuticals?

CASI Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 151,200 shares, a decline of 33.0% from the October 31st total of 225,700 shares. Based on an average daily volume of 30,600 shares, the short-interest ratio is currently 4.9 days. Approximately 2.5% of the company's shares are short sold. View CASI Pharmaceuticals' Short Interest .

When is CASI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our CASI earnings forecast .

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.27. The biotechnology company earned $9.82 million during the quarter, compared to analyst estimates of $10.09 million. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 110.90% and a negative net margin of 95.24%.

When did CASI Pharmaceuticals' stock split?

Shares of CASI Pharmaceuticals reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA) , OPKO Health (OPK) , Caladrius Biosciences (CLBS) , Overstock.com (OSTK) , Riot Platforms (RIOT) , Boeing (BA) , Enphase Energy (ENPH) , Catalyst Pharmaceuticals (CPRX) , Pure Storage (PSTG) and QUALCOMM (QCOM) .

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James Huang, Weihao Xu and Wei-Wu He . View institutional ownership trends .

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

CASI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CASI)

$5.59

0.00 (0.00%)

(As of 12/1/2023 ET)

Compare

Today's Range: $5.38
▼
$5.68
50-Day Range: $2.00
▼
$5.85
52-Week Range: $1.45
▼
$5.94

Volume: 22,379 shs
Average Volume: N/A
Market Capitalization: $74.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

CASI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 114.7% Upside
$12.00 Price Target
Short Interest: Healthy
2.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.50
Upright™ Environmental Score
News Sentiment: 0.96
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

246th out of 957 stocks

Biological Products, Except Diagnostic Industry

34th out of 159 stocks

3.5

Analyst's Opinion

Consensus Rating
CASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, CASI Pharmaceuticals has a forecasted upside of 114.7% from its current price of $5.59.
Amount of Analyst Coverage
CASI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.52% of the float of CASI Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
CASI Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in CASI Pharmaceuticals has recently decreased by 33.01%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
CASI Pharmaceuticals does not currently pay a dividend.
Dividend Growth
CASI Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CASI Pharmaceuticals has received a 62.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Melphalan" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for CASI Pharmaceuticals is -1.50.

3.3

News and Social Media Coverage

News Sentiment
CASI Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for CASI Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for CASI on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
4 people have added CASI Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 14.62% of the stock of CASI Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of CASI Pharmaceuticals is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CASI Pharmaceuticals is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CASI Pharmaceuticals has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CASI Pharmaceuticals Stock (NASDAQ:CASI)

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CASI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CASI Stock News Headlines

November 29, 2023 | americanbankingnews.com

CASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.com

November 15, 2023 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for CASI Pharmaceuticals: Here's What You Need To Know

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 14, 2023 | markets.businessinsider.com

CASI Pharmaceuticals Posts Narrower Loss In Q3

November 14, 2023 | msn.com

CASI Pharmaceuticals GAAP EPS of -$0.35, revenue of $8.84M

November 14, 2023 | finance.yahoo.com

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

November 8, 2023 | markets.businessinsider.com

CASI : Juventas' CNCT 19 Approved In China For R/R B-cell Acute Lymphoblastic Leukemia Treatment

August 14, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for CASI Pharmaceuticals (CASI)

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

August 11, 2023 | markets.businessinsider.com

CASI Pharmaceuticals, Inc. Q2 Loss Widens

August 11, 2023 | msn.com

CASI Pharmaceuticals GAAP EPS of -$0.77, revenue of $9.82M

August 11, 2023 | finance.yahoo.com

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

August 10, 2023 | msn.com

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)

August 10, 2023 | msn.com

ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates

August 1, 2023 | finance.yahoo.com

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

July 20, 2023 | finance.yahoo.com

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

July 20, 2023 | finance.yahoo.com

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

July 10, 2023 | finance.yahoo.com

Switch Therapeutics Appoints Douglas Fambrough, Ph.D., to Board of Directors

June 28, 2023 | finance.yahoo.com

CASI - CASI Pharmaceuticals, Inc.

May 28, 2023 | finance.yahoo.com

We Think CASI Pharmaceuticals (NASDAQ:CASI) Needs To Drive Business Growth Carefully

May 17, 2023 | finanznachrichten.de

CASI Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results

May 17, 2023 | finance.yahoo.com

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

May 3, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Cytosorbents (CTSO)

April 26, 2023 | msn.com

CASI Pharmaceuticals GAAP EPS of -$3.01 misses by $2.64, revenue of $43.12M beats by $32.31M

April 26, 2023 | finance.yahoo.com

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

April 26, 2023 | finance.yahoo.com

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

April 17, 2023 | finance.yahoo.com

Improved Revenues Required Before CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock's 114% Jump Looks Justified

See More Headlines

Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/11/2023
Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/24/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CASI
CUSIP: N/A
CIK: 895051
Web: www.casipharmaceuticals.com
Phone: 861065086063
Fax: 301-315-2437
Employees: 224
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.00
High Stock Price Target: $12.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +114.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,010,000.00
Net Margins: -95.24%
Pretax Margin: -87.15%
Return on Equity: -110.90%
Return on Assets: -47.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.91
Quick Ratio: 4.17

Sales & Book Value

Annual Sales: $43.11 million
Price / Sales: 1.73
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.16 per share
Price / Book: 2.59

Miscellaneous

Outstanding Shares: 13,320,000
Free Float: 10,492,000
Market Cap: $74.46 million
Optionable: Not Optionable
Beta: N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Wei-Wu He Ph.D. (Age 58)
Chairman & CEO
Comp: $565.36k
Dr. Wei Zhang Ph.D. (Age 63)
President
Comp: $1.13M
Dr. Alexander A. Zukiwski M.D. (Age 66)
Executive VP & Chief Medical Officer
Comp: $514.79k
Ms. Kun Qian (Age 41)
VP & Global Controller
Ms. Chunhua Wang (Age 51)
Chief Operating Officer
Ms. Wei Gao (Age 42)
General Counsel
Dr. James E. Goldschmidt Ph.D.
Chief Business Development Officer
Mr. Fuqiang Zhang (Age 54)
Chief Commercial Officer
Ms. Amanda Cui
VP & Global Controller

Key Competitors

View All Competitors

CASI Stock Analysis - Frequently Asked Questions

Should I buy or sell CASI Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CASI shares.
View CASI analyst ratings or view top-rated stocks.
What is CASI Pharmaceuticals' stock price target for 2024?: 1 Wall Street analysts have issued 12-month price targets for CASI Pharmaceuticals' shares. Their CASI share price targets range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 114.7% from the stock's current price.
View analysts price targets for CASI or view top-rated stocks among Wall Street analysts.
How have CASI shares performed in 2023?: CASI Pharmaceuticals' stock was trading at $1.79 at the start of the year. Since then, CASI stock has increased by 212.3% and is now trading at $5.59.
View the best growth stocks for 2023 here.
Are investors shorting CASI Pharmaceuticals?: CASI Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 151,200 shares, a decline of 33.0% from the October 31st total of 225,700 shares. Based on an average daily volume of 30,600 shares, the short-interest ratio is currently 4.9 days. Approximately 2.5% of the company's shares are short sold.
View CASI Pharmaceuticals' Short Interest.
When is CASI Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our CASI earnings forecast.
How were CASI Pharmaceuticals' earnings last quarter?: CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.27. The biotechnology company earned $9.82 million during the quarter, compared to analyst estimates of $10.09 million. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 110.90% and a negative net margin of 95.24%.

When did CASI Pharmaceuticals' stock split?: Shares of CASI Pharmaceuticals reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of CASI Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).
Who are CASI Pharmaceuticals' major shareholders?: CASI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James Huang, Weihao Xu and Wei-Wu He.
View institutional ownership trends.
How do I buy shares of CASI Pharmaceuticals?: Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CASI) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CASI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CASI)

CASI Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™